Although it is not clear if suppression of pERK is associated with clinical response, the rapid recovery of pERK in our study may represent a mechanism for the lack of benefit seen in this trial, by allowing tumor regrowth and/or selection of resistant clones in tumors. Here, EIF2AK3 is linked to neoplasm.